We appreciate Arginon
et al.‘s interest on our paper. We agree that the overall odds ratio of 1.28 underestimates
the real impact of HDV superinfection on oncogenesis. We would like to point out,
however, that this figure is the consequence of including a great deal of studies
of weak quality. When the data quality is assured by a robust study design – such
as in prospective cohort studies – the OR is significantly increased, suggesting that
HDV may indeed be a potent carcinogen.
To read this article in full you will need to make a payment
Mechanisms of HBV-induced hepatocellular carcinoma.
J Hepatol. 2016; 64: S84-S101
Clinical outcome of acute and chronic hepatitis delta over time: a long-term follow-up study.
J Viral Hepat. 2011; 18: 434-442
A 28-year study of the course of hepatitis Delta infection: a risk factor for cirrhosis and hepatocellular carcinoma.
Gastroenterology. 2009; 136: 1629-1638
The oncogenic role of hepatitis delta virus in hepatocellular carcinoma.
JHEP Rep. 2019; 1: 120-130
Molecular signature and mechanisms of hepatitis D virus-associated hepatocellular carcinoma.
Mol Cancer Res MCR. 2018; 16: 1406-1419
Delta hepatitis within the Veterans Affairs medical system in the United States: prevalence, risk factors, and outcomes.
J Hepatol. 2015; 63: 586-592
Epidemiological, clinical, biological and virological factors influencing the occurrence of hepatocellular carcinoma and validation of predictive scores in 317 HBV-related cirrhotic patients. Prospective study Cir-B nested in the ANRS CO12 CirVir cohort.
Hepatology. 2016; 63: 898A-899A
Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B.
Gut. 2000; 46: 420-426
Hepatocellular carcinoma in Italian patients with cirrhosis.
N Engl J Med. 1991; 325: 675-680
Published online: September 12, 2020
In Press Journal Pre-Proof
© 2020 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
Access this article on ScienceDirect